Today: 2 December 2025
Subscribe
Browse Category

NASDAQ:SRPT News 2 October 2025 - 25 November 2025

SRPT Stock Today, November 25, 2025: Sarepta Rises on SRP‑1003 Progress While Elevidys Risks Still Loom

SRPT Stock Today, November 25, 2025: Sarepta Rises on SRP‑1003 Progress While Elevidys Risks Still Loom

Shares of Sarepta Therapeutics (NASDAQ: SRPT) head into Tuesday’s session trying to build on a rare rally, as investors digest a positive safety update for its experimental RNA therapy SRP‑1003 and weigh it against fresh FDA warnings and trial setbacks
25 November 2025
 ·  ·  ·  ·  ·  · 
European Stocks Climb Despite Shutdown Fears – Healthcare and Luxury Lead Gains

Wall Street on Edge: Bank Chiefs Warn 10–15% Pullback as Fed Flies Blind—Futures Slide, Big Tech Wobbles (Nov. 4, 2025)

Live market snapshot (pre‑open) Timestamp: ~12:50 UTC (7:50 a.m. ET) — indicative live quotes. Index proxies (ETFs) Megacaps & key namesAAPL 269.05 • MSFT 517.03 • NVDA 206.88 • AMZN 254.00 • GOOGL 283.72 • AMD 259.65 • TSLA 468.37 •
4 November 2025
 ·  ·  ·  ·  ·  ·  ·  ·  ·  ·  ·  ·  ·  ·  ·  ·  · 
Sarepta Therapeutics (SRPT) Surges After FDA Greenlights Duchenne Gene Therapy – Is a Rebound Ahead?

Sarepta Therapeutics (SRPT) Surges After FDA Greenlights Duchenne Gene Therapy – Is a Rebound Ahead?

Stock Performance and Trends Sarepta’s stock is recovering some ground after steep losses. As of Oct 2, 2025, SRPT closed at $19.57, up about 6.8%for the day investing.com. This followed a general uptrend in recent weeks: SRPT is up roughly 16% over the last
2 October 2025
 ·  ·  ·  ·  ·  · 
Go toTop